Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to ...

The agreement will allow Enigma to use its PET imaging tracer PMI04 to visualize microglia activity in neurodegenerative ...

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its ...

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have ...

GE HealthCare is researching imaging tech for improved diagnosis and treatment of patients with cancer and neurodegenerative ...

Neuraly and Enigma Biomedical have signed an agreement for PMI04, a positron emission tomography (PET) imaging biomarker for ...

Cubresa’s NuPET™ is a revolutionary in-bore PET scanner that inserts into existing MRI instruments to create a powerful and flexible hybrid preclinical in vivo imaging platform that combines ...

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...

An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...

A new UCLA Health Jonsson Comprehensive Cancer Center-led study has revealed that advanced prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging could reveal ...

Niagara Falls, NY, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT ...